Homocysteine level and mechanisms of injury in Parkinson's disease as related to MTHFR, MTR, and MTHFD1 genes polymorphisms and L-Dopa treatment

Current Genomics

Volumn 14, Issue 8, 2013, Pages 534-542

  Rozycka, Agata ^a   Jagodzinski, Pawel P ^a   Kozubski, Wojciech ^a   Lianeri, Margarita ^a   Dorszewska, Jolanta ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Biothiols; MTHFD1 polymorphism; MTHFR; MTR; PD

Indexed keywords

5, 10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE; ICHTHAMMOL; LEVODOPA; METHIONINE SYNTHASE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; UNCLASSIFIED DRUG;

ARTICLE; COGNITIVE DEFECT; DNA METHYLATION; DNA POLYMORPHISM; GENE; GENOTYPE ENVIRONMENT INTERACTION; HOMOCYSTINURIA; HUMAN; MTHFD1 GENE; MTHFR GENE; MTR GENE; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; RISK FACTOR; VASCULAR DISEASE; VITAMIN INTAKE;

EID: 84894055607     PISSN: 13892029     EISSN: 18755488     Source Type: Journal    
DOI: 10.2174/1389202914666131210210559     Document Type: Article

References (99)

1. Muller, T.; Werne, B.; Fowler, B.; Kuhn, W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet, 1999, 354(9173), 126-127.
2. Sniezawska, A.; Dorszewska, J.; Rozycka, A.; Przedpelska-Ober, E.; Lianeri, M.; Jagodzinski, P.P.; Kozubski, W. MTHFR, MTR, and MTHFD1 gene polymorphisms compared to homocysteine and asymmetric dimethylarginine concentrations and their metabolites in epileptic patients treated with antiepileptic drugs. Seizure, 2011, 20(7), 533-540.
3. Bots, M.L.; Launer, L.J.; Lindemans, J.; Hofman, A.; Grobbee, D.E. Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: The Rotterdam Study. J. Intern. Med., 1997, 242(4), 339-347.
4. Bostom, A.G.; Rosenberg, I.H.; Silbershatz, H.; Jacques, P.F.; Selhub, J.; D'Agostino, R.B.; Wilson, P.W.; Wolf, P.A. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann. Intern. Med., 1999, 131(5), 352-355.
5. Seshadri, A.; Beiser, A.; Selhub, J.; Jacques, P.F.; Rosenberg, I.H.; D'Agostino, R.B.; Wilson, P.W.; Wolf, P.A. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med., 2002, 346(7), 476-483.
6. den Heijer, T, Vermeer, SE, Clarke, R, Oudkerk, M, Koudstaal, PJ, Hofman, A, Breteler, MM. Homocysteine and brain atrophy on MRI of non-demented elderly. Brain, 2003, 126(Pt 1), 170-175.
7. Zoccolella, S.; Martino, D.; Defazio, G.; Lamberti, P.; Livrea, P. Hyperhomocysteinemia in movement disorders: current evidence and hypotheses. Curr. Vasc. Pharmacol., 2006, 4(3), 237-243.
8. Dorszewska, J.; Florczak, J.; Rozycka, A.; Kempisty, B.; Jaroszewska-Kolecka, J.; Chojnicka, K.; Trzeciak, W.H.; Kozubski, W. Oxidative DNA damage and level of thiols as related to polymorphisms of MTHFR, MTR, MTHFD1 in Alzheimer's and Parkinson's diseases. Acta Neurobiol. Exp. (Wars), 2007, 67(2), 113-29.
9. Prins, N.D.; Den Heijer, T.; Hofman, A.; Koudstaal, P.J.; Jolles, J.; Clarke, R.; Breteler, M.M. Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study. Neurolology, 2002, 59(9), 1375-1380.
10. Isobe, C.; Murata, T.; Sato, C.; Terayama, Y. Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease. Life Sci., 2005, 77(15), 1836-1843.
11. O'Suilleabhain, P.E.; Sung, V.; Hernandez, C.; Lacritz, L.; Dewey, R. B Jr.; Bottiglieri, T.; Diaz-Arrastia, R. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch. Neurol., 2004, 61(6), 865-868.
12. Zoccolella, S.; Lamberti, P.; Iliceto, G.; Diroma, C.; Armenise, E.; Defazio, G.; Lamberti, S.V.; Fraddosio, A.; de Mari, M.; Livrea, P. Plasma homocysteine levels in L-dopa treated Parkinson's disease patients with cognitive dysfunctions. Clin. Chem. Lab. Med., 2005, 43(10), 1107-1110.
13. Hazra, A.; Kraft, P.; Lazarus, R.; Chen, C.; Chanock, S.J.; Jacques, P.; Selhub, J.; Hunter, D.J. Genome-wide significant predictors of metabolites in the one-carbon metabolism pathway. Hum. Mol. Genet., 2009, 18(23), 4677-4687.
14. Kruman, II.; Culmsee, C.; Chan, S.L.; Kruman, Y.; Guo, Z.; Penix, L.; Mattson, M.P.; Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J. Neurosci., 2000, 20(18), 6920-6926.
15. Suhara, T.; Fukuo, K.; Yasuda, O.; Tsubakimoto, M.; Takemura, Y.; Kawamoto, H.; Yokoi, T.; Mogi, M.; Kaimoto, T.; Ogihara, T. Homocysteine enhances endothelial apoptosis via upregulation of Fas-mediated pathways. Hypertension, 2004, 43(6), 1208-1213.
16. Mangiagalli, A.; Samuele, A.; Armentero, M.T.; Bazzini, E.; Nappi, G.; Blandini, F. Effects of homocysteine on apoptosisrelated proteins and anti-oxidant system in isolated human lymphocytes. Eur. J. Biochem., 2004, 271(9), 1671-1676.
17. Mattson, M.; Shea, T.B. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci., 2003, 26(3), 137-146.
18. Duan, W.; Ladenheim, B.; Cutler, R.G.; Kruman, II.; Cadet, J.L.; Mattson, M.P. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J. Neurochem., 2002, 80(1), 101-110.
19. Imamura, K.; Takeshima, T.; Nakaso, K.; Nakashima, K. Homocysteine is toxic for dopaminergic neurons in primary mesencephalic culture. Neuroreport, 2007, 18(13), 1319-1322.
20. Chandra, G.; Gangopadhyay, P.K.; Senthil Kumar, K.S.; Mohanakumar, K.P. Acute intranigral homocysteine administration produces stereotypic behavioral changes and striatal dopamine depletion in Sprague-Dawley rats. Brain Res., 2006, 1075(1), 81-92.
21. Tjiattas, L.; Ortiz, D.O.; Dhivant, S.; Mitton, K.; Rogers, E.; Shea, T.B. Folate deficiency and homocysteine induce toxicity in cultured dorsal root ganglion neurons via cytosolic calcium accumulation. Aging Cell, 2004, 3(2), 71-76.
22. Zoccolella, S.; Martino, D.; Defazio, G.; Lamberti, P.; Livrea, P. Hyperhomocysteinemia in movement disorders: current evidence and hypotheses. Curr. Vasc. Pharmacol., 2006, 4(3), 237-243.
23. dos Santos, E.F.; Busanello, E.N.; Miglioranza, A.; Zanatta, A.; Barchak, A.G.; Vargas, CR.; Saute, J.; Rosa, C.; Carrion, M.J.; Camargo, D.; Dalbem, A.; da Costa, J.C.; de Sousa Miguel, S.R.; de Mello Rieder, C.R.; Wajner, M. Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease. Metab. Brain Dis., 2009, 24(2), 257-269.
24. Kuhn, W.; Roebroek, R.; Blom, H.; van Oppenraaij, D.; Przuntek, H.; Kretschmer, A.; Büttner, T.; Woitalla, D.; Müller, T. Elevated plasma levels of homocysteine in Parkinson's disease. Eur. Neurol., 1998, 40(4), 225-227.
25. Rogers, J.D.; Sanchez-Saffon, A.; Frol, A.B.; Diaz-Arrastia, R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch. Neurol., 2003, 60(1), 59-64.
26. Yasui, K.; Kowa, H.; Nakaso, K.; Takeshima, T.; Nakashima, K. Plasma homocyssteine and MTHFR C677T genotype in levodopatreated patients with PD. Neurology, 2000, 55(3), 437-440.
27. Blandini, F.; Fancellu, R.; Martignoni, E.; Mangiagalli, A.; Pacchetti, C.; Samuele, A.; Nappi, G. Plasma homocysteine and l-dopa metabolism in paatients with Parkinson's disease. Clin. Chem., 2001, 47(6), 1102-1104.
28. Sato, Y.; Iwamoto, J.; Kanoko, T.; Satoh, K. Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. Am. J. Med., 2005, 118(11), 1250-1255.
29. Florczak, J.; Dorszewska, J.; Kozubski, W. Influence of L-dopa treatment duration on the level of oxidative damage to DNA and thiol compound concentration in patients with Parkinson's disease. Neurol. Neurochir. Pol. (in Polish)., 2008, 42(1Suppl.1), S36-S44.
30. Carta, M.; Lindgren, H.S.; Lundblad, M.; Stancampiano, R.; Fadda, F.; Cenci, M.A. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J. Neurochem., 2006, 96(6), 1718-1727.
31. Ceravolo, R.; Cossu, G.; Bandettini di Poggio, M.; Santoro, L.; Barone, P.; Zibetti, M.; Frosini, D.; Nicoletti, V.; Manganelli, F.; Iodice, R.; Picillo, M.; Merola, A.; Lopiano, L.; Paribello, A.; Manca, D.; Melis, M.; Marchese, R.; Borelli, P.; Mereu, A.; Contu, P.; Abbruzzese, G.; Bonuccelli, U. Neuropathy and levodopa in Parkinson's disease: Evidence from a multicenter study. Mov. Disord., 2013; doi: 10.1002/mds.25585.
32. Kikuchi, A.; Takeda, A.; Onodera, H.; Kimpara, T.; Hisanaga, K.; Sato, N.; Nunomura, A.; Castellani, R.J.; Perry, G.; Smith, M.A.; Itoyama, Y. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol. Dis., 2002, 9(2), 244-248.
33. Dorszewska, J.; Kempisty, B.; Jaroszewska-Kolecka, J.; Rozycka, A.; Florczak, J.; Lianeri, M.; Jagodzinski, P.P.; Kozubski, W. Expression and polymorphisms of gene 8-oxoguanine glycosylase 1 and the level of oxidative DNA damage in peripheral blood lymphocytes of patients with Alzheimer's disease. DNA Cell Biol., 2009, 28(11), 579-588.
34. Alam, Z.I.; Jenner, A.; Daniel, S.E.; Lees, A.J.; Cairns, N.; Marsden, C.D.; Jenner, P.; Halliwell, B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem., 1997, 69(3), 1196-1203.
35. Zhang, J.; Perry, G.; Smith, M.A.; Robertson, D.; Olson, S.J.; Graham, D.G.; Montine, T.J. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol., 1999, 154(5), 1423-1429.
36. Jenner, P. Oxidative stress in Parkinson's disease. Ann. Neurol., 2003, 53(Suppl.3), S26-S36; discussion S36-8.
37. Schapira, A.H.; Cooper, J.M.; Dexter, D.; Clark, J.B.; Jenner, P.; Marsden, C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem., 1990, 54(3), 823-827.
38. Spencer, J.P.; Jenner, A.; Aruoma, O.I.; Evans, P.J.; Kaur, H.; Dexter, D.T.; Jenner, P.; Lees, A.J.; Marsden, D.C.; Halliwell, B. Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease. FEBS Lett., 1994, 353(3), 246-250.
39. Prigione, A.; Begni, B.; Galbussera, A.; Beretta, S.; Brighina, L.; Garofalo, R.; Andreoni, S.; Piolti, R.; Ferrarese, C. Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: negative correlation with levodopa dosage. Neurobiol. Dis., 2006, 23(1), 36-43.
40. Botto, N.; Andreassi, M.G.; Manfredi, S.; Masetti, S.; Cocci, F.; Colombo, M.G.; Storti, S.; Rizza, A.; Biagini, A. Genetic polymorphisms in folate and homocysteine metabolism as risk factors for DNA damage. Eur. J. Hum. Genet., 2003, 11(9), 671-678.
41. Tanaka, T.; Scheet, P.; Giusti, B.; Bandinelli, S.; Piras, M.G.; Usala, G.; Lai, S.; Mulas, A.; Corsi, A.M.; Vestrini, A.; Sofi, F.; Gori, A.M.; Abbate, R.; Guralnik, J.; Singleton, A.; Abecasis, G.R.; Schlessinger, D.; Uda, M.; Ferrucci, L. Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. Am. J. Hum. Genet., 2009, 84(4), 477-482.
42. Miller, J.W.; Selhub, J.; Nadeau, M.R.; Thomas, C.A.; Feldman, R.G.; Wolf, P.A. Effect of L-dopa on plasma homocysteine in PD Patients: relationship to B-vitamin status. Neurolog, 2003, 60(7), 1125-1129.
43. Lamberti, P.; Zoccolella, S.; Armenise, E.; Lamberti, S.V.; Fraddosio, A.; de Mari, M.; Iliceto, G.; Livrea, P. Hyperhomocysteinamia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate dministration. Eur. J. Neurol., 2005, 12(5), 365-368.
44. Ueland, P.M.; Hustad, S.; Schneede, J.; Refsum, H.; Vollset, S.E. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol. Sci., 2001, 22(4), 195-201.
45. D'Angelo, A.; Mazzola, G.; Fermo, I. Gene-gene and geneenvironmental interactions in mild hyperhomocysteinemia. Pathophysiol. Haemost. Thromb., 2003, 33(5-6), 337-341.
46. Kluijtmans, L.A.; Young, I.S.; Boreham, C.A.; Murray, L.; McMaster, D.; McNulty, H.; Strain, J.J.; McPartlin, J.; Scott, J.M.; Whitehead, A.S. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood, 2003, 101(7), 2483-2488.
47. Agnati, L.F.; Genedani, S.; Rasio, G.; Galantucci, M.; Saltini, S.; Filaferro, M.; Franco, R.; Mora, F.; Ferre, S.; Fuxe, K. Studies on homocysteine plasma levels in Alzheimer's patients. Relevance for neurodegeneration. J. Neural. Transm., 2005, 112(1), 163-169.
48. Morrison, L.D.; Smith, D.D.; Kish, S.J. Brain Sadenosylmethionine levels are severely decreased in Alzheimer's disease. J. Neurochem., 1996, 67(3), 1328-1331.
49. Kim, H.C.; Yamada, K.; Nitta, A.; Olariu, A.; Tran, M.H.; Mizuno, M.; Nakajima, A.; Nagai, T.; Kamei, H.; Jhoo, W.K.; Im, D.H.; Shin, E.J.; Hjelle, O.P.; Ottersen, O.P.; Park, S.C.; Kato, K.; Mirault, M.E.; Nabeshima, T. Immunocytochemical evidence that amyloid beta (1-42) impairs endogenous antioxidant system in vivo. Neuroscience, 2003, 119(2), 399-419.
50. Fuso, A.; Seminara, L.; Cavallaro, R.A.; D'Anselmi, F.; Scarpa, S. S-adenosylmethionine /homocysteine cycle alterations modify DNA methylaction status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol. Cell. Neurosci., 2005, 28(1), 195-204.
51. Cheng, H.; Gomes-Trolin, C.; Aquilonius, S.M.; Steinberg, A.; Lofberg, C.; Ekblom, J.; Oreland, L. Levels of L-methionine Sadenosyltransferase activity in erythrocytes and concentrations of S-adenosylmethionine and Sadenosylhomocysteine in whole blood of patients with Parkinson's disease. Exp. Neurol., 1997, 145(2Pt.1), 580-585.
52. Miner, S.E.; Evrovski, J.; Cole, D.E. Clinical chemistry and molecular biology of homocysteine metabolism: an update. Clin. Biochem., 1997, 30(3), 189-201.
53. Toohey JI, Sulfane Possible Involvement of sulfur in homocysteine-induced atherosclerosis. Med. Hypotheses. 2001, 56(2), 259-261.
54. Blundell, G.; Jones, B.G.; Rose, F.A.; Tudball, N. Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis, 1996, 122(2), 163-172.
55. Agnati, L.F.; Ferré, S.; Genedani, S.; Leo, G.; Guidolin, D.; Filaferro, M.; Carriba, P.; Casadó, V.; Lluis, C.; Franco, R.; Woods, A.S.; Fuxe, K. Allosteric modulation of dopamine D2 receptors by homocysteine. J. Proteome Res., 2006, 5(11), 3077-3083.
56. Zoccolella, S.; Lamberti, P.; Iliceto, G.; Dell'Aquila, C.; Diroma, C.; Fraddosio, A.; Lamberti, S.V.; Armenise, E.; Defazio, G.; de Mari, M.; Livrea, P. Elevated plasma homocysteine levels in Ldopa-treated Parkinson's disease with dyskinesias. Clin. Chem. Lab. Med., 2006, 44(7), 863-866.
57. Gorell, J.M.; Johnson, C.C.; Rybicki, B.A. Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology, 1994, 44(10), 1865-1868.
58. Muller, T. Role of homocysteine in the treatment of Parkinson's disease. Expert Rev. Neurother., 2008, 8(6), 957-967.
59. Muller, T.; Kuhn, W. Cysteine elevation in levodopa-treated patients with Parkinson's disease. Mov. Disord., 2009, 24(6), 929-932.
60. 12 and serum total homocysteine levels in confirmed Alzheimer disease. Arch. Neurol., 1998, 55(11), 1449-55.
61. Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. Alpha-synuclein in Lewy bodies. Nature, 1997, 388(6645), 839-840.
62. Hsu, L.J.; Sagara, Y.; Arroyo, A.; Rockenstein, E.; Sisk, A.; Mallory, M.; Wong, J.; Takenouchi, T.; Hashimoto, M.; Masliah, E. Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol., 2000, 157(2), 401-410.
63. Bergman, H.; Feingold, A.; Nini, A.; Raz, A.; Slovin, H.; Abeles, M.; Vaadia, E. Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates. Trends Neurosci., 1998, 21(1), 32-38.
64. Jenner, P. Oxidative stress in Parkinson's disease. Ann. Neurol., 2003, 53(Suppl.3), S26-36, discussion S36-38.
65. Migliore, L.; Petrozzi, L.; Lucetti, C.; Gambaccini, G.; Bernardini, S.; Scarpato, R.; Trippi, F.; Barale, R.; Frenzilli, G.; Rodilla, V.; Bonuccelli, U. Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology, 2002, 58(12), 1809-1815.
66. Mecocci, P.; Polidori, M.C.; Ingegni, T.; Cherubini, A.; Chionne, F.; Cecchetti, R.; Senin, U. Oxidative damage to DNA in lymphocytes from AD patients. Neurology, 1998, 51(4), 1014-7.
67. Dorszewska, J.; Florczak, J.; Kozubski, W. Level of oxidative DNA damage and expression of apoptotic proteins in patients with Parkinson's disease treatment with L-dopa. Abstracts of the XVIII WFN World Congress on Parkinson's Disease and Related Disorders. Parkinsonism Relat. Disord., 2009, 5(Suppl.2), S111.
68. Cornetta, T.; Palma, S.; Aprile, I.; Padua, L.; Tonali, P.; Testa, A.; Cozzi, R. Levodopa therapy reduces DNA damage in peripheral blood cells of patients with Parkinson's disease. Cell Biol Toxicol., 2009, 25(4), 230-321.
69. Spencer, J.P.; Jenner, P.; Halliwell, B. Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease. Neuroreport, 1995, 6(11), 1480-1484.
70. Dorszewska, J.; Florczak, J.; Rózycka, A.; Jaroszewska-Kolecka, J.; Trzeciak, W.H.; Kozubski, W. Polymorphisms of the CHRNA4 gene encoding the alpha4 subunit of nicotinic acetylcholine receptor as related to the oxidative DNA damage and the level of apoptotic proteins in lymphocytes of the patients with Alzheimer's disease. DNA Cell Biol., 2005, 24(12), 786-94.
71. Miller, J.W.; Shukitt-Hale, B.; Villalobos-Molina, R.; Nadeau, M.R.; Selhub, J.; Joseph, J.A. Effect of L-Dopa and the catechol-Omethyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin. Neuropharmacol., 1997, 20(1), 55-66.
72. Yasui, K.; Nakaso, K.; Kowa, H.; Takeshima, T.; Nakashima, K. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol. Scand., 2003, 108(1), 66-67.
73. O'Suilleabhain, P.E.; Bottiglieri, T.; Dewey, R.B.; Sharma, S.; Diaz-Arrastia, R. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. Mov. Disord., 2004, 19(12), 1403-1408.
74. Jara-Prado, A.; Ortega-Vazquez, A.; Martinez-Ruano, L.; Rios, C.; Santamaria, A. Homocysteine-induced brain lipid peroxidation: effects of NMDA receptor blockade, antioxidant treatment, and nitric oxide synthase inhibition. Neurotox. Res., 2003, 5(4), 237-243.
75. Kang, S.S.; Zhou, J.; Wong, P.W.; Kowalisyn, J.; Strokosch, G. Intermediate homocysteinemia a thermolabile variant of methyle netetrahydrofolate reductase. Am. J. Hum. Genet., 1988, 43(4), 414-421.
76. Frosst, P.; Blom, H.J.; Milos, R.; Goyette, P.; Sheppard, C.A.; Matthews, R.G.; Boers, G.J.; den Heijer, M.; Kluijtmans, L.A.; van den Heuvel, L.P.; Rozen, R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet., 1995, 10(1), 111-113.
77. Bagley, P.J.; Selhub, J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc. Natl. Acad. Sci. USA, 1998, 95(22), 13217-13220.
78. Pejchal, R.; Campbell, E.; Guenther, B.D.; Lennon, B.W.; Matthews, R.G.; Ludwig, M.L. Structural perturbations in the Ala → Val polymorphism of methylenetetrahydrofolate reductase: how binding of folates may protect against inactivation. Biochemistry, 2006, 45(15), 4808-4818.
79. Klerk, M.; Verhoef, P.; Clarke, R.; Blom, H.J.; Kok, F.J.; Schouten, E.G. MTHFR Studies Collaboration Group. MTHFR 677C → T polymorphism and risk of coronary heart disease: a metaanalysis. JAMA, 2002, 288(16), 2023-2031.
80. Nakaso, K.; Yasui, K.; Kowa, H.; Kusumi, M.; Ueda, K.; Yoshimoto, Y.; Takeshima, T.; Sasaki, K.; Nakashima, K. Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-dopa, homocysteine, and MTHFR genotype. J. Neurol. Sci., 2003, 207(1-2), 19-23.
81. Weisberg, I.; Tran, P.; Christensen, B.; Sibani, S.; Rozen, R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol. Genet. Metab.,1998, 64(3), 169-172.
82. van der Put, N.M.; Steegers-Theunissen, R.P.; Frosst, P.; Trijbels, F.J.; Eskes, T.K.; van den Heuvel, L.P.; Mariman, E.C.; den Heyer, M.; Rozen, R.; Blom, H.J. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet, 1995, 346(8982), 1070-1071.
83. van der Put, N.M.; Gabreëls, F.; Stevens, E.M.; Smeitink, J.A.; Trijbels, F.J.; Eskes, T.K.; van den Heuvel, L.P.; Blom, H.J. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am. J. Hum. Genet., 1998, 62(5), 1044-1051.
84. Anello, G.; Gueant-Rodriguez, R.M.; Bosco, P.; Gueant, J.L.; Romano, A.; Namour, B.; Spada, R.; Caraci, F.; Pourie, G.; Daval, J.L.; Ferri, R. Homocysteine and methylenetetrahydrofolate reductase polymorphism in Alzheimer's disease. Neuroreport, 2004, 15(5), 859-861.
85. Religa, D.; Czyzewski, K.; Styczynska, M.; Peplonska, B.; Lokk, J.; Chodakowska-Zebrowska, M.; Stepien, K.; Winblad, B.; Barcikowska, M. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. Neurosci. Lett., 2006, 404(1-2), 56-60.
86. McIlroy, S.P.; Dynan, K.B.; Lawson, J.T.; Patterson, C.C.; Passmore, A.P. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke, 2002, 33(10), 2351-2356.
87. Brunelli, T.; Bagnoli, S.; Giusti, B.; Nacmias, B.; Pepe, G.; Sorbi, S.; Abbate, R. The C677T methylenetetrahydrofolate reductase mutation is not associated with Alzheimer's disease. Neurosci. Lett., 2001, 315(1-2), 103-105.
88. Wakutani, Y.; Kowa, H.; Kusumi, M.; Nakaso, K.; Isoe-Wada, K.; Yano, H.; Urakami, K.; Tekeshima, T.; Nakashima, K. The regulatory region polymorphisms of the MTHFR gene are not associated with Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 2004, 17(3), 147-150.
89. Wakutani, Y.; Kowa, H.; Kusumi, M.; Nakaso, K.; Isoe-Wada, K.; Yano, H.; Urakami, K.; Tekeshima, T.; Nakashima, K. A haplotype of the methylenetetrahydrofolate reductase gene is protective against late-onset Alzheimer's disease. Neurobiol. Aging, 2004, 25(3), 291-294.
90. Fong, C.S.; Shyu, H.Y.; Shieh, J.C.; Fu, Y.P.; Chin, T.Y.; Wang, H.W.; Cheng, C.W. Association of MTHFR, MTR, and MTRR polymorphisms with Parkinson's disease among ethnic Chinese in Taiwan. Clin. Chim. Acta, 2011, 412(3-4), 332-338.
91. Todorović, Z.; Dzoljić, E.; Novaković, I.; Mirković, D.; Stojanović, R.; Nesić, Z.; Krajinović, M.; Prostran, M.; Kostić, V. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. J. Neurol. Sci., 2006, 248(1-2), 56-61.
92. Yuan, R.Y.; Sheu, J.J.; Yu, J.M.; Hu, C.J.; Tseng, I.J.; Ho, C.S.; Yeh, C.Y.; Hung, Y.L.; Chiang, T.R. Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopatreated and non-treated Parkinson's disease patients. J. Neurol. Sci., 2009, 287(1-2), 64-68.
93. Białecka, M.; Kurzawski, M.; Roszmann, A.; Robowski, P.; Sitek, E.J.; Honczarenko, K.; Gorzkowska, A.; Budrewicz, S.; Mak, M.; Jarosz, M.; Goła{ogonek}b-Janowska, M.; Koziorowska-Gawron, E.; Droździk, M.; Sławek, J. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease. Pharmacogenet. Genomics, 2012, 22(10), 716-724.
94. Jarrett, J.T.; Amaratunga, M.; Drennan, C.L.; Scholten, J.D.; Sands, R.H.; Ludwig, M.L.; Matthews, R.G. Mutations in the B12-binding region of methionine synthase: how the protein controls methylcobalamin reactivity. Biochemistry, 1996, 35(7), 2464-2475.
95. Watkins, D.; Ru, M.; Hwang, H.Y.; Kim, C.D.; Murray, A.; Philip, N.S.; Kim, W.; Legakis, H.; Wai, T.; Hilton, J.F.; Ge. B.; Dore, C.; Hosack, A.; Wilson, A.; Gravel, R.A.; Shane, B.; Hudson, T.J.; Rosenblatt, D.S. Hyperhomocysteinemia due to methionine synthase deficiency, cblG: structure of the MTR gene, genotype diversity, and recognition of a common mutation, P1173L. Am. J. Hum. Genet., 2002, 71(1), 143-153.
96. Matsuo, K.; Suzuki, R.; Hamajima, N.; Ogura, M.; Kagami, Y.; Taji, H.; Kondoh, E.; Maeda, S.; Asakura, S.; Kaba, S.; Nakamura, S.; Seto, M.; Morishima, Y.; Tajima, K. Association between polymorphisms of folate-and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. Blood, 2001, 97(10), 3205-3209.
97. McCaddon, A.; Regland, B.; Hudson, P.; Davies, G. Functional vitamin B(12) deficiency and Alzheimer disease. Neurology, 2002, 58(9), 1395-1399.
98. Barlowe, C.K.; Appling, D.R. Molecular genetic analysis of Saccharomyces cerevisiae C1-tetrahydrofolate synthase mutants reveals a noncatalytic function of the ADE3gene product and an additional folate-dependent enzyme. Mol. Cell. Biol., 1990, 10(11), 5679-5687.
99. Hol, F.A.; van der Put, N.M.; Geurds, M.P.A.; Heil, S.G.; Trijbels, F.J.; Hamel, B.C.; Mariman, E.C.; Blom, H.J. Molecular genetic analysis of the gene encoding the trifunctional enzyme MTHFD (methylenetetrahydrofolate-dehydrogenase, methenyltetrahydrofolate-cyclohydrolase, formyltetrahydrofolate synthetase) in patients with neural tube defects. Clin. Genet., 1998, 53(2), 119-125.